HK1209047A1 - 新型藥物組合物 - Google Patents

新型藥物組合物

Info

Publication number
HK1209047A1
HK1209047A1 HK15109780.8A HK15109780A HK1209047A1 HK 1209047 A1 HK1209047 A1 HK 1209047A1 HK 15109780 A HK15109780 A HK 15109780A HK 1209047 A1 HK1209047 A1 HK 1209047A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
novel pharmaceutical
novel
composition
pharmaceutical
Prior art date
Application number
HK15109780.8A
Other languages
English (en)
Inventor
Gossett Campbell
Francisco Henriquez
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HK1209047A1 publication Critical patent/HK1209047A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
HK15109780.8A 2012-11-30 2015-10-07 新型藥物組合物 HK1209047A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
PCT/US2013/071816 WO2014085371A1 (en) 2012-11-30 2013-11-26 Novel pharmaceutical composition

Publications (1)

Publication Number Publication Date
HK1209047A1 true HK1209047A1 (zh) 2016-03-24

Family

ID=50828398

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109780.8A HK1209047A1 (zh) 2012-11-30 2015-10-07 新型藥物組合物

Country Status (29)

Country Link
US (2) US20150328320A1 (zh)
EP (2) EP2925299B1 (zh)
JP (1) JP6232443B2 (zh)
KR (1) KR102206432B1 (zh)
CN (2) CN107970214A (zh)
AR (1) AR093648A1 (zh)
AU (1) AU2013352369B2 (zh)
BR (1) BR112015012111A8 (zh)
CA (1) CA2891346A1 (zh)
CL (1) CL2015001459A1 (zh)
EA (2) EA028246B1 (zh)
ES (1) ES2686730T3 (zh)
HK (1) HK1209047A1 (zh)
IL (3) IL266415B2 (zh)
IN (1) IN2015DN04094A (zh)
MA (1) MA38121A1 (zh)
MX (1) MX2015006867A (zh)
MY (1) MY170427A (zh)
NZ (1) NZ628395A (zh)
PE (1) PE20151024A1 (zh)
PH (1) PH12015501168A1 (zh)
PL (1) PL2925299T3 (zh)
PT (1) PT2925299T (zh)
SG (1) SG11201503688SA (zh)
TN (1) TN2015000198A1 (zh)
TW (2) TW201831187A (zh)
UY (1) UY35157A (zh)
WO (1) WO2014085371A1 (zh)
ZA (1) ZA201503346B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
JP2019535696A (ja) * 2016-11-25 2019-12-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピリドン誘導体の医薬組成物およびその製造方法
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
AU2020370625A1 (en) * 2019-10-22 2022-05-26 Chemistry Rx Methods for treating congenital epidermal hyperplasia
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
CA2727841A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
DE602005026556D1 (de) * 2004-12-07 2011-04-07 Proteolix Inc Zusammensetzung zur proteasomhemmung
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
EP2952197B1 (en) * 2005-10-26 2017-04-26 CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
BRPI0806590A2 (pt) * 2007-01-16 2013-07-23 Bipar Sciences Inc formulaÇÕes para o tratamento de cÂncer
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
FI4159217T3 (fi) * 2009-10-16 2024-08-15 Novartis Ag Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä
WO2012062743A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US20130023531A1 (en) * 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
AU2012223639B2 (en) * 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
EA024890B1 (ru) * 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
CN107970214A (zh) 2018-05-01
EP2925299A4 (en) 2016-06-29
US20150328320A1 (en) 2015-11-19
PE20151024A1 (es) 2015-07-27
EA201791411A1 (ru) 2018-03-30
ZA201503346B (en) 2016-01-27
PH12015501168A1 (en) 2015-08-10
TW201831187A (zh) 2018-09-01
BR112015012111A2 (pt) 2017-07-11
ES2686730T3 (es) 2018-10-19
MY170427A (en) 2019-07-31
JP6232443B2 (ja) 2017-11-15
CL2015001459A1 (es) 2015-12-18
IL266415B2 (en) 2024-03-01
IL238971A0 (en) 2015-07-30
EP2925299A1 (en) 2015-10-07
US20170189408A1 (en) 2017-07-06
PL2925299T3 (pl) 2018-11-30
AU2013352369A1 (en) 2015-05-28
WO2014085371A1 (en) 2014-06-05
IL266415A (en) 2019-06-30
MA38121A1 (fr) 2016-10-31
IL266415B1 (en) 2023-11-01
AU2013352369B2 (en) 2016-07-28
IL300664A (en) 2023-04-01
BR112015012111A8 (pt) 2018-01-23
KR20150091352A (ko) 2015-08-10
KR102206432B1 (ko) 2021-01-22
PT2925299T (pt) 2018-10-16
EA028246B1 (ru) 2017-10-31
AR093648A1 (es) 2015-06-17
IN2015DN04094A (zh) 2015-10-09
JP2016501874A (ja) 2016-01-21
EA201591047A1 (ru) 2015-11-30
UY35157A (es) 2014-06-30
MX2015006867A (es) 2015-10-05
SG11201503688SA (en) 2015-06-29
CN104902876A (zh) 2015-09-09
EP2925299B1 (en) 2018-06-06
TW201434468A (zh) 2014-09-16
CN104902876B (zh) 2018-01-19
EP3400933A1 (en) 2018-11-14
CA2891346A1 (en) 2014-06-05
TN2015000198A1 (en) 2016-10-03
IL238971B (en) 2019-05-30
NZ628395A (en) 2016-10-28

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
ZA201501930B (en) Pharmaceutical composition
HK1209638A1 (zh) 藥物組合物
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
HK1203812A1 (zh) 新型藥物製劑
GB201118232D0 (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
IL266415A (en) Innovative pharmaceutical composition
HK1189158A1 (zh) 藥用組合物
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
ZA201502987B (en) Pharmaceutical composition
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100444A2 (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
EP2727594A4 (en) NEW PHARMACEUTICAL COMPOSITION
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100445A2 (en) Pharmaceutical composition
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions